Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYTO NK-203
- Development stage
- Preclinical
- Lead developer
- CytoImmune Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CYTO NK-203 is an off-the-shelf, allogeneic chimeric antigen receptor (CAR) natural killer (NK) cell therapy derived from umbilical cord blood. It is engineered to express a CAR targeting prostate stem cell antigen (PSCA), and incorporates a soluble, secretable form of interleukin-15 (IL-15) to enhance the activity and persistence of the NK cells. The therapy is designed for direct cytotoxicity against cancer cells expressing PSCA and for broad stimulation of both innate and adaptive immune responses via IL-15 secretion. Preclinical studies have demonstrated robust anti-tumor activity in models of pancreatic cancer, with prolonged survival observed in treated mice. CYTO NK-203 is being developed by CytoImmune Therapeutics in collaboration with City of Hope, primarily targeting solid tumors such as pancreatic cancer and non-small cell lung cancer[1][2][3][5][7].
- Other names
- PSCA-CAR NK cells
02
Targets
PSCA (Prostate stem cell antigen)IL15 (Interleukin 15)
Beyond the preview
Go deeper on CYTO NK-203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYTO NK-203.